165 results about "Virus strain" patented technology

The application discloses an isolation method of bovine epidemic fever virus and the bovine epidemic fever virus obtained by the method and application of the bovine epidemic fever virus, and belongs to the technical field of bovine epidemic fever virus isolation. The application aims to provide an efficient and rapid method for isolating bovine epidemic fever virus. The application provides the isolation method of the bovine epidemic fever virus, wherein the anticoagulated blood sample of a bovine is inoculated on KC cells for culture, the virus is harvested, the BHK-21 cells are inoculated to grow into a monolayer, and the first generation of passage cells with cytopathic effect is obtained by passage. The virus strain can also be used for screening, preparation and detection of bovine epidemic fever virus antibodies, and for preparation of an animal model infected by the bovine epidemic fever virus.

The application discloses a disease transmission link prediction method and system based on a dynamic hypergraph neural network, aiming to comprehensively depict virus transmission paths and risk levels from multiple dimensions. First, data is collected from a gene database, mobile device logs and clinical texts, virus variation characteristics, population contact relationships and symptom semantic information are extracted respectively, and a dynamic hypergraph that integrates virus strain nodes, individual nodes and regional nodes is constructed. The hyperedge is defined according to molecular similarity, space-time contact and semantic overlap, and the weight is dynamically adjusted according to the transmission intensity of the infectious disease. A multi-modal hypergraph neural network with variation perception is introduced to jointly model and adaptively fuse multiple types of hyperedges and multi-scale features, output node propagation embedding vectors and predict potential transmission chains, perform prevention and control responses, and realize real-time deployment and feedback loop in an edge-cloud collaborative manner, ensuring efficient and accurate infectious disease transmission modeling and intervention control while ensuring data privacy.

The invention relates to the technical field of viruses, in particular to a construction method and application of an African swine fever virus strain. According to the invention, the three virulence genes MGF110-9L, EP402R and I73R of the African swine fever virus are taken as targets for the first time to construct a virus strain with deletion of the three virulence genes, and the virus strain is found to be capable of effectively reducing the virus toxicity but retaining better immunogenicity, can improve the immunity of an organism to the African swine fever virus, and has a relatively great application prospect.

The invention discloses a disease transmission link prediction method and system based on a dynamic hypergraph neural network, and aims to comprehensively describe a virus transmission path and a risk level from multiple dimensions. The method comprises the following steps: firstly, collecting data from a gene database, a mobile equipment log and a clinical text, respectively extracting virus variation characteristics, a crowd contact relationship and symptom semantic information, and constructing a dynamic hypergraph fusing virus strain nodes, individual nodes and region nodes; the hyperedge is defined according to molecular similarity, space-time contact and semantic overlap, and the weight is dynamically adjusted along with the infectious disease transmission intensity. A multi-modal hypergraph neural network of variation perception is introduced, joint modeling and adaptive fusion are performed on multi-type hyperedge and multi-scale features, a node propagation embedded vector is output, a potential propagation chain is predicted, prevention and control response is executed, and real-time deployment and feedback closed loop are realized in an edge-cloud cooperation mode. And efficient and accurate infectious disease transmission modeling and intervention control are completed on the premise of ensuring data privacy.

The invention provides an application of nigericin in preparation of an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drug, and belongs to the technical field of antiviral drugs. Experimental results show that the nigericin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the nigericin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

The invention provides a Garlu virus attenuated strain and application thereof, and relates to the field of virology and biological medicine. According to the invention, the screened Garlu virus attenuated strain is a natural attenuated strain derived from a tick sample, can grow in Vero cells, has the titer of more than or equal to 107 TCID50 / mL, does not have clinical pathogenicity to an immunodeficient host, and is safe; after the attenuated strain is used as an immunogen for pre-intervention, infection of a lethal virus strain can be avoided, the survival rate is increased to 100%, adverse effects on growth and life of experimental animals are avoided, particularly, a host can be stimulated to generate humoral immunity and cellular immunity at the same time, and the survival rate of the experimental animals is improved. And moreover, broad-spectrum cross-protection efficacy can be generated on Bandavirus lethal virus strains, and a foundation is laid for improvement of research on Bandavirus live vaccines such as the Colu virus and the like.

The invention relates to the technical field of biological detection, and particularly discloses an ELISA kit for detecting a neutralizing antibody of a severe fever with thrombocytopenia syndrome virus and an application method of the ELISA kit. The ELISA kit comprises an ELISA plate on which SFTSV receptor LRP1 protein is fixed, and an enzyme-labeled SFTSV Gn-8M, wherein the SFTSV receptor LRP1 protein is fixed on the ELISA plate; the SFTSV Gn-8M is an SFTSV membrane protein Gn mutant designed by the invention, and can be specifically combined with an SFTSV receptor LRP1 protein on an elisa plate, and compared with a standard virus strain Gn protein, the self-designed SFTSV Gn-8M has amino acid mutation of eight sites, has stronger combining capacity with a host cell receptor, and can be used for detecting the SFTSV. The kit disclosed by the invention has the characteristics of high safety, high efficiency, high flux, high specificity, high sensitivity, high stability and the like, and is suitable for large-scale rapid screening of the neutralizing antibody of the severe fever with thrombocytopenia syndrome virus.

The invention belongs to the field of veterinary biological products, and relates to a porcine reproductive and respiratory syndrome virus strain and application thereof. The invention particularly discloses a porcine reproductive and respiratory syndrome virus strain with a microbial preservation number of CGMCC (China General Microbiological Culture Collection Center) No.47095. The invention also discloses a vaccine composition prepared from the strain. After pigs are inoculated with the vaccine composition, the vaccine composition can resist challenge of a porcine reproductive and respiratory integrated virus SD strain and a porcine reproductive and respiratory integrated virus HuN4 strain, and has application prospects.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

The application belongs to the technical field of biology, and discloses a kind of Myzus persicae densovirus, amplification and connector method and its application, Myzus persicae densovirus name is Myzus persicae densovirus 2, abbreviated as MpDV2, preserved in China typical culture preservation center, and the preservation number is V202281.The Myzus persicae densovirus MpDV2 provided in the application is a virus strain that has not been isolated and identified before and has pathogenicity to Myzus persicae, and the full-length sequence of the genome of the Myzus persicae densovirus MpDV2 (including the complete terminal inverted repeat sequence) is disclosed for the first time, and the influence of the virus infection on the growth and development of Myzus persicae and the population dynamics / growth.The Myzus persicae densovirus MpDV2 of the application significantly reduces the intrinsic growth rate (r), net reproduction rate (R0) and week-long growth rate (lambda) of Myzus persicae population, and prolongs the average generation time (T) of the population, and the MpDV2 infection has a significant influence on the growth and development of Myzus persicae and population growth.

The invention belongs to the field of veterinary virology, and discloses a bovine ephemeral fever virus strain and reverse genetic application thereof, and the reverse genetic steps are as follows: taking pCI plasmid as a skeleton to prepare plasmid for expressing a complete genome of bovine ephemeral fever virus; the method comprises the following steps: respectively preparing auxiliary plasmids for expressing an N protein gene, a P protein gene, an L protein gene and a G protein gene of the bovine ephemeral fever virus by taking pCAGGS plasmids as a skeleton, co-transfecting BHK-21 cells by using the five plasmids, and culturing the cells to obtain the rescued bovine ephemeral fever virus. The rescued bovine ephemeral fever virus has no obvious difference from the reproductive capacity of the parent virus, and the genome is still stable after 10 generations of continuous passage in BHK-21 cells. The invention provides methodological support for genetic modification of the bovine ephemeral fever virus, and has an application prospect.

The invention provides application of periplocin in preparation of anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drugs, and belongs to the technical field of antiviral drugs. Experimental results show that periplocin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the periplocin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

The invention uses ex vivo human airway cultures to assess the transmissibility and replication ability of influenza and coronavirus strains. By comparing the pandemic influenza A H1N1 and the highly pathogenic influenza A H5N1 as reference virus strains, the spreading risks of various viruses are evaluated and classified. In addition, an in vitro model is used to assess the degree of alveolar fluid clearance (AFC) impairment caused by the virus as an indicator of the severity of the disease. The research reveals the relevance among the virus replication ability, human transmission, AFC damage degree and clinical disease severity of different influenza and coronavirus strains in bronchus.

The invention discloses a preparation method of a DNA (deoxyribonucleic acid) vaccine for preventing canine distemper, which comprises the following steps: taking plasmids of genes containing a newly separated canine distemper virus strain, namely a canine distemper virus fusion protein with an amino acid sequence shown as SEQ ID NO.6 and / or a hemagglutinin protein with an amino acid sequence shown as SEQ ID NO.8 as immunogens; hUO, mPEG-DMG, distearoyl phosphatidylcholine and cholesterol are used as lipid materials to prepare the canine distemper lipid nanoparticle DNA vaccine, and the vaccine can effectively stimulate neutralizing antibodies of mice, dogs, foxes and raccoon dogs and has clinical practical prospects.

The present invention relates to the technical field of biomedicine, and specifically to an inactivated hepatitis A vaccine and a preparation method thereof. The steps include: cell amplification, virus culture, virus harvesting, cell disruption, ultrafiltration concentration, inactivation, purification, and finished product; the virus culture step is: isolating from the feces of hepatitis A patients and obtaining virus strains through adaptive passage; adding a carrier to the bioreactor for sterilization and standby use, inoculating the virus strain into the collected cell suspension and transferring it to the bioreactor for culture; the cell disruption step is: ultrasonically vibrating the collected virus harvest liquid to obtain a cell disruption liquid; adding chloroform for extraction, centrifuging, and collecting the supernatant virus liquid. The present invention provides a preparation method for an inactivated hepatitis A vaccine, which prepares an efficient, safe, and stable inactivated hepatitis A vaccine by optimizing the virus culture and inactivation process. The method has the advantages of high virus yield and low production cost, and is suitable for large-scale production and application.

The invention belongs to the technical field of virus and gene engineering, and particularly relates to an expression vector of a respiratory syncytial virus (RSV) ON1 genotype consensus sequence strain and an editing strain, a reverse genetic manipulation system and an application of the reverse genetic manipulation system of the respiratory syncytial virus ON1 genotype consensus sequence strain and the editing strain of the RSV ON1 genotype consensus sequence strain and the editing strain of the respiratory syncytial virus ON1 genotype consensus sequence strain. According to the invention, an RSV-ON1 genotype consensus sequence strain is firstly constructed and saved, on the basis, 72 nucleotides which are repeatedly inserted into a G gene of the consensus sequence strain are removed through a gene editing technology, and two strains with different virus G gene sequences are obtained. According to the invention, through construction of RSV infectious clone edited by RSV-ON1 genotype G gene and rescue of the two strains, a fast, simple and accurate RSV reverse genetic system is constructed, and the RSV reverse genetic system can be applied to research on RSV in-vitro virus replication mechanism and pathogenesis and neutralizing antibody immune escape. A etiological technical platform is provided for research, development and evaluation of RSV vaccines, antibodies, drugs and the like.

The application belongs to the field of vaccines and genetic engineering technology, and relates to an H3N2 canine influenza recombinant virus strain and application thereof. Specifically, the application relates to a recombinant canine influenza vaccine strain which is obtained by recombination of the following genes: an HA gene, an NA gene, a PB1 gene, a PB2 gene, a PA gene, an NP gene, an M gene and an NS gene; wherein the sequence of the HA gene is shown as SEQ ID NO:1; and / or the sequence of the NA gene is shown as SEQ ID NO:2. The application also relates to an H3N2 canine influenza recombinant vaccine and a method for preparing the H3N2 canine influenza recombinant vaccine.

The invention belongs to the field of biology, and particularly relates to construction of a recombinant Seneca virus strain with Seneca virus 2B protein translation block site mutation. The 26th lysine (K) of the 2B protein is found to be a key site for inhibiting the translation of the host protein for the first time, and after the 26th K of the 2B protein is mutated into the alanine (A), the translation retardation phenomenon of the host protein is obviously weakened; secondly, the 26th K of the 2B protein is mutated into A to construct infectious clone, and the recombinant Seneca virus strain rSVA-2B K26A with 2B protein translation retardation site mutation is successfully rescued and obtained, compared with wild type SVA, after the rSVA-2B K26A infects host cells, the translation retardation phenomenon of the host cells is weakened, the expression level of host antiviral inflammatory cytokines is enhanced, and the expression level of the recombinant Seneca virus strain rSVA-2B K26A is improved. The Seneca virus vaccine strain can be used as a potential vaccine candidate strain, and a foundation is laid for developing a novel prevention and control strategy aiming at the Seneca virus.

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5′ copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5′ copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and / or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

The invention provides a construction method of an HBV (Hepatitis B Virus) infection model based on multilineage hepatobiliary organs, which comprises the following steps: differentiating human pluripotent stem cells to form immune cell-containing hepatobiliary organs for further maturation culture, and enabling the hepatobiliary organs to be mature in function and highly express NTCP (Natriuretic Therapeutic Cells) by using a maturation culture medium containing bile metabolism substrate cholesterol and deoxybear bile acid, so as to obtain the HBV infection model based on the multilineage hepatobiliary organs. And then infecting the mature organs by adopting an HBV virus strain generated by HepAD38 cells to construct an in-vitro model which is susceptible to HBV and can maintain an infection state for a long time. According to the construction method, the liver infection and immune interaction microenvironment can be simulated more truly, and a stable and reliable experimental platform is provided for HBV infection mechanism research and anti-HBV drug screening.

The invention discloses a peste des petits ruminants virus strain with a microbial preservation number of CCTCC (China Center For Type Culture Collection) NO: V202487. A DNA vaccine and an RNA vaccine which are prepared by taking proteins coded by the H gene and the F gene of the strain as immunogens have good immunogenicity and immune protection capacity. The strain has an application prospect.

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus E2 protein and application, and relates to the technical field of biology.The recombinant E2 protein provided by the application successfully realizes high-level expression of the E2 protein by removing the transmembrane region of the E2 protein and using the 18aa signal peptide of the E2 protein itself and a pig albumin signal peptide.The recombinant PRV expressing the classical swine fever virus (CSFV) E2 protein can induce E2 antibodies and cellular immunity after immunization of mice.The recombinant pseudorabies virus strain provided by the application can be used as a bivalent vaccine for preventing CSFV and PRV infection.

The invention relates to the technical field of biology, in particular to a virus preservative based on sodium dehydroacetate and a preparation method and application of the virus preservative. The virus preservative based on sodium dehydroacetate is prepared from the following components in percentage by weight: 1% of sodium dehydroacetate, 1% of potassium sorbate, 0.4% of trehalose, 0.008% of thiomersalate sodium salt and the balance of deionized water. By adopting the liquid preservative, the production standard of the virus preparation is reduced, and the production cost and the technical complexity are reduced; through suitability comparison, it is found that the preservative does not affect the activity of the virus strain, and the virus titer is not reduced after 100 h. Compared with a single preservative, the preservative disclosed by the invention has the advantages that the bacteriostatic ability is stronger, microorganisms in the preparation are obviously inhibited under the room temperature condition, and the detected microbial biomass is the lowest in each group, so that the preservative disclosed by the invention has a good continuous preservative effect on viruses, and the activity of the viruses can be maintained for a longer time.

The invention belongs to the field of biological products and the field of nucleic acid vaccines, and particularly relates to a virus (oropravirus)-like particle, preparation and application of the virus (oropravirus)-like particle as a vaccine. The virus-like particles are Oropers virus-like particles, and the virus-like particles contain proteins encoded by M genome segments of OROV strains or proteins encoded by gene segments of the M genome segments and N proteins of the OROV strains; wherein the corresponding sequence can also be a consistency sequence with the similarity of 75% with the corresponding sequence. Meanwhile, the particle VLP is used as a serum binding antibody of an antigen and an evaluation method of a T cell reaction, and the method can be used for detecting a serum lifting method after vaccine immunization. The invention further provides five nucleic acid vaccines for coding different functional domains of the OROV and combinations thereof, the immunogenicity and T cell reaction induced by the nucleic acid vaccines under different design strategies are displayed, strong body fluid and cell reaction is still kept 154 days after immunization, and it is proved that the nucleic acid vaccines can induce lasting and efficient immune reaction, and the immunogenicity and the T cell reaction are not influenced. The method can be used as a technical reserve and has huge clinical significance and application scenarios.

The invention provides a bovine nodular skin disease virus double-gene deletion strain as well as a vaccine and application thereof, and belongs to the technical field of biological medicines. The bovine nodular skin disease virus (LSDV) double-gene-deleted strain is characterized in that the virus strain is named as rLSDV-DoubMut, the preservation number of the virus strain is CGMCC NO: 46988, the preservation unit is China General Microbiological Culture Collection Center, the preservation time is December 23, 2025, the bovine nodular skin disease virus single-gene-deleted strain LSDV-005 is used as a parent strain, the bovine nodular skin disease virus single-gene-deleted strain LSDV-005 is used as a parent strain, the bovine nodular skin disease virus single-gene-deleted strain LSDV-005 is used as a parent strain, and the bovine nodular skin disease virus single-gene-deleted strain LSDV-005 is used as a parent strain. The gene is constructed by knocking out an ORF131 gene. The rLSDV-DoubMut has the advantages of genetic stability, high safety, strong immunogenicity and the like, and immune animals and wild virus infected animals can be distinguished through a 131 protein-based detection method.

The invention relates to a multi-antigen component PEI lipid delivery system and an anti-avian influenza virus multivalent vaccine comprising the same, belongs to the technical field of biological medicines, and provides a delivery system consisting of PEI, squalene, cholesterol and mPEG. The preparation method comprises the following steps of: constructing mRNA (messenger ribonucleic acid) molecules and a composite vaccine antigen system consisting of prokaryotic expression purified H7N9 avian influenza NP antigen, loading the composite vaccine antigen system into a delivery system to obtain the nanoparticles with a virus-like structure, and displaying the HA protein antigen and the NP antigen in the structure of the nanoparticles in a particle form by the nanoparticles, so that the nanoparticles can be used for preparing the H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza virus. And the mRNA molecule for coding the NA antigen, which is combined with the mRNA molecule, can be delivered into a cell in a manner of fusing lipid and a cell membrane, so that the mRNA molecule can be effectively expressed to induce a body to generate specific antibody reactions aiming at HA, NA and NP, and the body can also generate specific CTL reactions aiming at HA, NA and NP of different influenza virus strain subtypes.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

The invention discloses a coronavirus attenuated strain, a vaccine as well as a preparation method and application of the coronavirus attenuated strain. Compared with a natural strain, the coronavirus attenuated strain disclosed by the invention at least comprises deletion of a No.5 stem loop (Stem-loop 5, SL5) from the 131 site to the 350 site of a 5 '-non-coding region (5' UTR) or mutation of any nucleotide maintaining a stem loop structure in a second stem loop from the 175 site to the 299 site of the SL5; compared with a natural strain, the virulence of the SL5-deleted mutant virus strain is obviously reduced; the SL5-deficient mutant virus strain has better genetic stability, and the carried virus genome has no risk of being integrated into the host cell genome. Therefore, the coronavirus attenuated strain disclosed by the invention can be used as an attenuated live vaccine for preventing coronavirus infection, and has a good application prospect.

Systems for determining COVID include a protein biosensor that interacts with human biological sample and outputs the first and second signals; a wireless communication device; a memory device with detectors integrated into the memory device. The protein biosensor is configured to use two different biological components separated by an internal membrane within the protein biosensor. The concentration of the first biological component is the limit concentration for the first virus strain and the concentration of the second biological component is the limit concentration for the second virus strain. The memory device is configured to receive the first and second signals and set the first and second signal thresholds for each integrated detector. The memory device identifies the presence of the first or second virus strain in response to integrated detectors are detecting a value that is greater than or less than the first or second signal threshold.